Navigation Links
Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
Date:5/13/2009

Results Show Superior Decrease in Pain Scores Compared to Saline

PARSIPPANY, N.J., May 13 /PRNewswire/ -- Ferring Pharmaceuticals recently presented the results of a six-month safety and efficacy study demonstrating that EUFLEXXA(R) (1% sodium hyaluronate) was effective at decreasing the pain of knee osteoarthritis (OA) at 26 weeks. The study showed that EUFLEXXA (R) is superior to saline in decreasing pain at 26 weeks in patients with OA of the knee.(1) The study results were presented by Dr. Roy D. Altman in a poster at the Annual Meeting of the American Academy of Orthopedic Surgeons on February 23, 2009.

EUFLEXXA(R) is a three-injection treatment regimen indicated for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. The goal of hyaluronic acid (HA) therapy is to reduce pain and improve physical function by replenishing the HA in human synovial fluid (fluid in joints). In OA, this fluid becomes thinner, leading to a decrease in elasticity and viscosity.

About the Study

The multicenter, 26-week, randomized, double-blind trial compared EUFLEXXA(R) and intra-articular buffered saline (IA-SA) for level of pain following a 50-Foot Walk Test, measured by 100 mm visual analog scale (VAS). The 586 patients with chronic idiopathic knee OA were randomized to treatment with either product in a 1:1 ratio. Each patient received one weekly injection for 3 weeks with 9 follow-up visits over 26 weeks after the first injection.

The EUFLEXXA(R) group showed an advantage over saline in pain reduction, with a larger mean decrease from baseline in pain scores: -25.7 (28.9) mm versus -18.5(32.5) mm respectively, with a least squares means of -6.6 mm (P=0.002). At 26 weeks, 145 (58%) of EUFLEXXA(R) subjects reported a greater than or equal to 20-mm improvement in pain based on the VAS scoring, compared with 120 (46%) in the o
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
2. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., NEW YORK, Nov. 25 Reportlinke...is available in its catalogue: ,, Intranasal D...ttp://www.reportlinker.com/p0164267/Intranasal-Dru..., The US intranasal drug delivery market is witnes... the delivery of conventional local therapeutic dr...
(Date:11/25/2009)... FRAMINGHAM, Mass. and SYDNEY, Nov. 25 /PRNewswire...aq: HTWR ; ASX: HIN), a leading innovator and pro...upport technologies revolutionizing the treatment ... is scheduled to make an investor presentation at ...ce at 8:00 am EST on Wednesday, December 2, 2009. ...
(Date:11/24/2009)..., BETHESDA, Md., Nov. 24 /PRNewswire-Asia/ -... CHDX ), a leading independent American provider ... People,s Republic of China, today,announced that ...ray,"Unplugged" Health Care Conference, to be held...l. , Management is currently scheduled to...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City 2Chindex International to Present at Piper Jaffray Health Care Conference 2Mass General team develops potentially safer general anesthetic 52483 1Mass General team develops potentially safer general anesthetic 52483 2Frost 26 Sullivan Recognizes MIRTEC With the 2009 Award for Automated Optical Inspection Product Innovation of the Year 9325 1Frost 26 Sullivan Recognizes MIRTEC With the 2009 Award for Automated Optical Inspection Product Innovation of the Year 9325 2Frost 26 Sullivan Recognizes MIRTEC With the 2009 Award for Automated Optical Inspection Product Innovation of the Year 9325 3KLOS 26 Red Cross Set to Rock SoCal With Massive 5 Day Blood Drive 52478 1KLOS 26 Red Cross Set to Rock SoCal With Massive 5 Day Blood Drive 52478 2KLOS 26 Red Cross Set to Rock SoCal With Massive 5 Day Blood Drive 52478 3
...Successful and seamless completion of clinical tri...ened to randomized patients, market research, an e...ent guided by real time metrics. , , MediciGloba...chievable when clinical trial sites are engaged an...great team chemistry with the study sponsor -- a m...
...atRx Pharmaceuticals, a privately-held biopharmace...ted enrollment in the Company,s second pivotal Pha...blets). Together with the previously completed fir...any has fully enrolled its planned pivotal Phase 3...gen-free oral therapy currently in development for...
Other Medicine Technology:Major Restless Legs Study Completes Enrollment With Support From MediciGlobal 2QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy 2QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy 3
(Date:11/27/2009)... Specialist manufacturers who...ucts are saving millions of dollars by bringing in...ocess. Increasing numbers of pro-active medical ma...ts at the concept stage of their projects, ensurin...g design processes or potentially outdated technol...
(Date:11/26/2009)... , PRINCETON, N.J., Nov. 27 ... almost double over the next 25 years and annual m... $336 billion, up from $113 billion today, accordi...Diabetes Care . The National Changing Diabetes &...ommissioned the analysis by a team from the Univer...
(Date:11/26/2009)...age that,s too big or too heavy can lead to strain...Day News) -- There may be nothing wrong with stuff...t want to do the same thing with your suitcase as ...people were treated in 2008 in U.S. hospital emerg...dical facilities for luggage-related injuries, suc...
(Date:11/26/2009)... Dr. David Kim of the Live Li...surgery in Dallas , is one of a growing number of ...cial networking sites to connect with individuals ...nt to fight morbid obesity. Dr. Kim is utilizing F...mation about his practice with the community. , ...
(Date:11/26/2009)... Ennis & Ennis, P.A. is o... for users of Yaz and Yasmin birth control pills w...monary Embolism, Stroke, Heart Attack or other rel...ed. Women can call toll free at 1-800-856-6405 or ...slaw.com and fill out an online case evaluation f...
Breaking Medicine News(10 mins):Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3
...g in the October issue of the journal Pediatrics s...lk is more than that of Cow's milk. Dr. Ruth...New York and her colleague Dr. William H. Bowen us... when they were fed sweet liquids like soda and ho...
...ed in the treatment of Multiple Sclerosis (MS), ha...s taking the drug complained of neurological disor...gressive Multifocal Leukoencephalopathy (PML) is b...h work by blocking passage of immune cells in to t...
...rize meant swallowing a glassful of dangerous bact...ssor Barry Marshall however did just that. He swal...ach ulcers are bacterial in origin rather than str...ates for Medicine in the current year. "I didn't t...
...10 countries estimated to have the highest number ...US following closely. Type II Diabetes, one of the...ining // epidemic proportions throughout the world...idity and mortality due to long-term micro and mac...
...as advanced so much to the extent of replacing los...ing artificial implants. These implantable devices...od // alternative to the conventional treatment. ...ality of these tiny, yet useful devices. Designed ...
... been reported at a seniors' home in Toronto and e... have caused the death of four residents at the ho... that there was // no cause to fear an outbreak an... a significant burden of disease," he said. All th...
Other Medicine News:Health News:Nobel For Ulcer-Defying Aussie Scientists 2Health News:A new anti diabetic drug on the anvil 2Health News:Implantable devices to be powered by organosilicon compounds in the future 2
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
Medicine Products: